Evolus, Inc. - EOLS STOCK NEWS

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, has announced its upcoming Investor Day scheduled for September 12, 2024 in New York City. The event will be held at the "SECOND Floor" venue and will offer both in-person and webcast participation options. Starting at 7:30 a.m. ET with breakfast, formal presentations will begin at 8:00 a.m. ET and conclude by 12:00 p.m. ET.

During the event, Evolus' management team will provide detailed insights into the company's strategic vision, investment strategies, growth levers, and financial outlook. The presentations will be followed by a Q&A session. Pre-registration is required for both in-person and webcast attendees. A replay of the webcast and supporting materials will be made available on the Evolus website after the event.

Evolus, Inc. (NASDAQ: EOLS) has launched Nuceiva® (prabotulinumtoxinA) in Australia, expanding its global footprint in the aesthetic market. This strategic move is part of the company's geographic expansion strategy, with Evolus Australia established to drive medical education, training, marketing, and sales to healthcare professionals in the medical aesthetics field.

Nuceiva® is approved by the Therapeutic Goods Administration (TGA) for temporarily improving the appearance of moderate to severe glabellar lines in adult patients. The product, known as Jeuveau® in the United States, has been the fastest-growing neurotoxin in the U.S. for three consecutive years. Evolus aims to offer this new treatment to patients by working closely with aesthetics healthcare professionals in Australia.

The company's expansion into Australia is led by Daniel Henry, with support from Dan Stewart, Vice President and General Manager of Evolus International. This launch is expected to fuel Evolus' global growth strategy and reinforce its position as a global leader in the aesthetics industry.

Evolus (NASDAQ: EOLS), a performance beauty company, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. Sandra Beaver, CFO of Evolus, will present at the event on Tuesday, August 13, 2024, from 12:30 – 12:55 PM ET.

The presentation will take the form of a fireside chat, which will be accessible to investors via a webcast on the Investor Relations page of the Evolus website. For those unable to attend live, a replay of the webcast will be available for 90 days following the presentation, providing ample opportunity for investors to gain insights into the company's growth strategies and performance.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio of consumer brands, has announced it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after U.S. financial markets close. The company will host a conference call and live webcast at 4:30 p.m. ET the same day to discuss the results, followed by a Q&A session.

Interested parties can participate in the conference call by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international), or by connecting to the live webcast on the Investor Relations page of the Evolus website. A telephonic replay will be available after the call, and an archived webcast can be accessed on the company's website.

Evolus (NASDAQ: EOLS), a performance beauty company, has appointed Albert G. White III to its Board of Directors, effective July 1. White is currently the President and CEO of The Cooper Companies and will also join Evolus' Compensation Committee.

Chairman Vik Malik emphasized White's extensive industry experience and leadership, noting that his expertise will support Evolus' transition from a single-product company to a multi-product beauty innovator. White expressed enthusiasm for joining Evolus at a pivotal time, highlighting the success of the company's flagship product, Jeuveau, and its promising pipeline of filler products.

White's extensive background includes roles as CEO, CFO, and Chief Strategy Officer at Cooper Companies, as well as positions in investor relations and treasury. Evolus' Board will now consist of seven directors, six of whom are independent.

Evolus (NASDAQ: EOLS) has submitted the final module of its premarket approval (PMA) application to the FDA for its Evolysse™ Lift and Evolysse™ Smooth dermal filler products, aimed at treating nasolabial folds (NLF). The submission is a significant milestone for the company, expecting FDA approval in the second half of 2025. The PMA includes data from a U.S. pivotal study involving 140 patients, comparing Evolysse™ fillers to Restylane-L. Both products met their primary endpoint of non-inferiority and showed superiority to Restylane-L at six months. Evolus aims to position Evolysse™ Lift as versatile for facial wrinkles and folds, while Evolysse™ Smooth offers a softer alternative.

Evolus has launched its botulinum toxin type A product, Nuceiva, in Spain, one of Europe's largest markets for aesthetic injectables. This move is part of Evolus's geographic expansion strategy.

Nuceiva is approved for the temporary improvement of moderate to severe glabellar lines in adults under 65. The launch signifies Evolus's commitment to growth by establishing a direct presence in key regions. Led by Maria Cudeiro, Evolus aims to work closely with Spanish healthcare professionals to offer effective treatments.

Nuceiva has shown promising results in three Phase III trials and two long-term safety studies, with side effects similar to other neurotoxins. The product is known as Jeuveau in the US and has been the fastest-growing neurotoxin there for three consecutive years.

Evolus, a performance beauty company, announced the grant of stock options and restricted stock units (RSUs) to 9 newly hired non-executive employees. The grants consist of options to purchase 30,778 shares and 29,546 RSUs under the 2023 Inducement Incentive Plan.

The stock options, with an exercise price of $11.69, have a 10-year term and vest over 4 years, while the RSUs vest 25% annually over four years. These measures were taken as inducement for new employees, in line with Nasdaq Listing Rule 5635(c)(4).

Evolus has announced positive topline results from a U.S. pivotal study for its dermal fillers, Evolysse™ Lift and Smooth. Presented at the 2024 SCALE Meeting, the study showed that both products met primary and secondary endpoints, demonstrating superiority over Restylane-L in improving nasolabial fold severity at multiple time points. The safety profiles of the products were similar to Restylane-L with no serious adverse events. Evolus plans to submit Premarket Approval applications to the FDA within the next 90 days, potentially expanding their market by 78%, complementing their neurotoxin Jeuveau®.